GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sequana Medical NV (GREY:SQNMF) » Definitions » LT-Debt-to-Total-Asset

Sequana Medical NV (Sequana Medical NV) LT-Debt-to-Total-Asset : 0.58 (As of Jun. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Sequana Medical NV LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sequana Medical NV's long-term debt to total assests ratio for the quarter that ended in Jun. 2023 was 0.58.

Sequana Medical NV's long-term debt to total assets ratio increased from Jun. 2021 (0.28) to Jun. 2023 (0.58). It may suggest that Sequana Medical NV is progressively becoming more dependent on debt to grow their business.


Sequana Medical NV LT-Debt-to-Total-Asset Historical Data

The historical data trend for Sequana Medical NV's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequana Medical NV LT-Debt-to-Total-Asset Chart

Sequana Medical NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only 0.77 0.27 0.53 0.53 0.49

Sequana Medical NV Quarterly Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.53 0.27 0.49 0.58

Sequana Medical NV LT-Debt-to-Total-Asset Calculation

Sequana Medical NV's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )/Total Assets (A: Dec. 2022 )
=13.561/27.569
=0.49

Sequana Medical NV's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (Q: Jun. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2023 )/Total Assets (Q: Jun. 2023 )
=15.69/27.223
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sequana Medical NV  (GREY:SQNMF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Sequana Medical NV LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Sequana Medical NV's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sequana Medical NV (Sequana Medical NV) Business Description

Comparable Companies
Traded in Other Exchanges
Address
Kortrijksesteenweg 1112 ,bus 102, Sint-Denijs-Westrem, Ghent, BEL, 9051
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies and over 750 implants. The company's geographical segments include Switzerland, Germany, the United Kingdom, and the Rest of the world, out of which Germany accounts for the majority of the revenue.

Sequana Medical NV (Sequana Medical NV) Headlines

No Headlines